EditForce develops drugs and seeds by using nucleic acid manipulation technologies.
EditForce develops drugs and seeds by using nucleic acid (DNA/RNA) manipulation technologies.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 26, 2021 | Series Unknown | ¥800M | 4 |
Newton Biocapital
|
— | Detail |
| Mar 1, 2019 | Series B | ¥870M | 6 | — | — | Detail |
| Feb 3, 2016 | Seed | ¥175M | 2 |
UTEC - The University of Tokyo Edge Capital Partners
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Newton Biocapital
|
Yes | Series Unknown |
Global Brain Corporation
|
— | Series Unknown |
ITOCHU Technology Ventures
|
— | Series Unknown |
UTEC - The University of Tokyo Edge Capital Partners
|
— | Series Unknown |
Japan Science and Technology Agency
|
— | Series B |
K4 Ventures
|
— | Series B |
QB Capital
|
— | Series B |
KISCO
|
— | Seed |